{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T02:27:59Z","timestamp":1786328879729,"version":"build-2736575974"},"reference-count":33,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Lab Hematology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Measurable residual disease (MRD) is a key prognostic marker for patient survival. This study evaluated concordance between 10\u2010color flow cytometry and next\u2010generation sequencing (NGS)\u2013based immunoglobulin heavy chain (IGH) gene assays for MRD detection and to assess prognostic significance in adult B\u2010cell acute lymphoblastic leukemia (B\u2010ALL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter prospective study enrolled 51 patients with newly diagnosed B\u2010ALL. Bone marrow samples were obtained at diagnosis, post\u2010induction (1\u2009month), and post\u2013early consolidation (3\u2009months). Flow cytometry and NGS\u2010IGH were performed at three timepoints to assess MRD B\u2010ALL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients were classified as high risk according to white blood cell count and cytogenetic features in 37.3% and 64.7% of patients, respectively. Treatment protocols included pediatric\u2010inspired regimens (41.2%), adult\u2010ALL protocols (52.9%), and low\u2010intensity chemotherapy. All 16 Philadelphia chromosome\u2013positive patients received tyrosine kinase inhibitors. Twenty patients underwent allogeneic hematopoietic cell transplantation (HCT) in first complete remission (CR). Median relapse\u2010free survival (RFS) and overall survival were 19 and 39\u2009months, respectively. MRD negativity at 3\u2009months by either method correlated with significantly superior RFS. Allogeneic HCT also conferred RFS benefit. MRD positive patients without HCT had the worst RFS. Flow cytometry MRD positivity at 3\u2009months independently predicted inferior RFS (HR 3.81; 95% CI 1.01\u201314.43). The overall concordance between flow cytometry and NGS was 80.7%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MRD positivity at 3\u2009months post\u2010treatment strongly predicted relapse, supporting its use to guide therapeutic modifications of B\u2010ALL. Apart from NGS\u2010based IGH clonality assays, 10\u2010color flow cytometry offers an alternative in resource\u2010limited settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ijlh.70216","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:29:01Z","timestamp":1786325341000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Laboratory Concordance and Prognostic Impact of 10\u2010Color Flow Cytometry and Next\u2010Generation Sequencing\u2010Based Immunoglobulin Gene Assay for Measurable Residual Disease Monitoring in Adult B\u2010Cell Acute Lymphoblastic Leukemia: A Multicenter Study From Thai Acute Leukemia Working Group (\n                    <scp>TALWG<\/scp>\n                    )"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5258-2140","authenticated-orcid":false,"given":"Chantiya","family":"Chanswangphuwana","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital  Bangkok Thailand"},{"name":"Center of Excellence in Translational Hematology Chulalongkorn University  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1451-7636","authenticated-orcid":false,"given":"Wasithep","family":"Limvorapitak","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine Thammasat University  Pathumthani Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2252-7586","authenticated-orcid":false,"given":"Sirorat","family":"Kobbuaklee","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital  Bangkok Thailand"},{"name":"Center of Excellence in Translational Hematology Chulalongkorn University  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patsita","family":"Kansuwan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital  Bangkok Thailand"},{"name":"Center of Excellence in Translational Hematology Chulalongkorn University  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9528-8681","authenticated-orcid":false,"given":"Kitsada","family":"Wudhikarn","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital  Bangkok Thailand"},{"name":"Center of Excellence in Translational Hematology Chulalongkorn University  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7912-1996","authenticated-orcid":false,"given":"Ponlapat","family":"Rojnuckarin","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital  Bangkok Thailand"},{"name":"Center of Excellence in Translational Hematology Chulalongkorn University  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1262-2005","authenticated-orcid":false,"given":"Weerapat","family":"Owattanapanich","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2731-4889","authenticated-orcid":false,"given":"Thanawat","family":"Rattanathammethee","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine Chiang Mai University  Chiang Mai Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2381-9292","authenticated-orcid":false,"given":"Adisak","family":"Tantiworawit","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine Chiang Mai University  Chiang Mai Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2679-4254","authenticated-orcid":false,"given":"Panachai","family":"Silpsamrit","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Phramongkutklao Hospital and College of Medicine  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-7600","authenticated-orcid":false,"given":"Kannadit","family":"Prayongratana","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Phramongkutklao Hospital and College of Medicine  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanakrit","family":"Piyajaroenkij","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1073-8872","authenticated-orcid":false,"given":"Dusit","family":"Jit\u2010ueakul","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Faculty of Medicine Vajira Hospital, Navamindradhiraj University  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6949-4449","authenticated-orcid":false,"given":"Chantana","family":"Polprasert","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital  Bangkok Thailand"},{"name":"Center of Excellence in Translational Hematology Chulalongkorn University  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,9]]},"reference":[{"issue":"19","key":"e_1_2_13_2_1","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.2023020794","article-title":"Diagnosis, Prognostic Factors, and Assessment of ALL in Adults: 2024 ELN Recommendations From a European Expert Panel","volume":"143","author":"G\u00f6kbuget N.","year":"2024","journal-title":"Blood"},{"issue":"19","key":"e_1_2_13_3_1","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of ALL in Adults: 2024 ELN Recommendations From a European Expert Panel","volume":"143","author":"G\u00f6kbuget N.","year":"2024","journal-title":"Blood"},{"issue":"2","key":"e_1_2_13_4_1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ajh.25338","article-title":"Recommendations for the Assessment and Management of Measurable Residual Disease in Adults With Acute Lymphoblastic Leukemia: A Consensus of North American Experts","volume":"94","author":"Short N. J.","year":"2019","journal-title":"American Journal of Hematology"},{"issue":"11","key":"e_1_2_13_5_1","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.bbmt.2019.08.014","article-title":"Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence\u2010Based Review From the American Society for Transplantation and Cellular Therapy","volume":"25","author":"DeFilipp Z.","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"7","key":"e_1_2_13_6_1","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta\u2010Analysis","volume":"3","author":"Berry D. A.","year":"2017","journal-title":"JAMA Oncology"},{"issue":"26","key":"e_1_2_13_7_1","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal Residual Disease Diagnostics in Acute Lymphoblastic Leukemia: Need for Sensitive, Fast, and Standardized Technologies","volume":"125","author":"Dongen J. J.","year":"2015","journal-title":"Blood"},{"issue":"2","key":"e_1_2_13_8_1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.blre.2016.09.006","article-title":"Monitoring Minimal Residual Disease in Acute Leukemia: Technical Challenges and Interpretive Complexities","volume":"31","author":"Chen X.","year":"2017","journal-title":"Blood Reviews"},{"issue":"12","key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","article-title":"Measurable Residual Disease in Acute Lymphoblastic Leukemia: Methods and Clinical Context in Adult Patients","volume":"107","author":"Saygin C.","year":"2022","journal-title":"Haematologica"},{"issue":"9","key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/s41375-019-0496-7","article-title":"Standardized Next\u2010Generation Sequencing of Immunoglobulin and T\u2010Cell Receptor Gene Recombinations for MRD Marker Identification in Acute Lymphoblastic Leukaemia; A EuroClonality\u2010NGS Validation Study","volume":"33","author":"Br\u00fcggemann M.","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"e_1_2_13_11_1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized Flow Cytometry for Highly Sensitive MRD Measurements in B\u2010Cell Acute Lymphoblastic Leukemia","volume":"129","author":"Theunissen P.","year":"2017","journal-title":"Blood"},{"issue":"6","key":"e_1_2_13_12_1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11899-018-0479-1","article-title":"Minimal\/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry","volume":"13","author":"Fuda F.","year":"2018","journal-title":"Current Hematologic Malignancy Reports"},{"issue":"4","key":"e_1_2_13_13_1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cyto.b.21833","article-title":"Applications of Flow Cytometric Immunophenotyping in the Diagnosis and Posttreatment Monitoring of B and T Lymphoblastic Leukemia\/Lymphoma","volume":"96","author":"DiGiuseppe J. A.","year":"2019","journal-title":"Cytometry Part B, Clinical Cytometry"},{"issue":"1","key":"e_1_2_13_14_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/ajcp\/aqaa242","article-title":"How I Diagnose Minimal\/Measurable Residual Disease in B Lymphoblastic Leukemia\/Lymphoma by Flow Cytometry","volume":"155","author":"Cherian S.","year":"2021","journal-title":"American Journal of Clinical Pathology"},{"issue":"8","key":"e_1_2_13_15_1","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1038\/bcj.2013.31","article-title":"Prognostic Significance of Monitoring Leukemia\u2010Associated Immunophenotypes by Eight\u2010Color Flow Cytometry in Adult B\u2010Acute Lymphoblastic Leukemia","volume":"3","author":"Weng X. Q.","year":"2013","journal-title":"Blood Cancer Journal"},{"key":"e_1_2_13_16_1","doi-asserted-by":"crossref","first-page":"957743","DOI":"10.3389\/fonc.2022.957743","article-title":"Clinical Implication of Minimal Residual Disease Assessment by Next\u2010Generation Sequencing\u2010Based Immunoglobulin Clonality Assay in Pediatric B\u2010Acute Lymphoblastic Leukemia","volume":"12","author":"Lee J. W.","year":"2022","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"e_1_2_13_17_1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12935-024-03404-3","article-title":"Monitoring Measurable Residual Disease in Paediatric Acute Lymphoblastic Leukaemia Using Immunoglobulin Gene Clonality Based on Next\u2010Generation Sequencing","volume":"24","author":"Ahn W. K.","year":"2024","journal-title":"Cancer Cell International"},{"issue":"7","key":"e_1_2_13_18_1","first-page":"982","article-title":"Laboratory Validation and Clinical Utility of Next\u2010Generation Sequencing\u2010Based IGH\/TCR Clonality Testing for the Monitoring of Measurable Residual Disease in Acute Lymphoblastic Leukaemia: Real\u2010World Experience at Austin Pathology","volume":"56","author":"Ma S. B.","year":"2024","journal-title":"Pathology"},{"issue":"2","key":"e_1_2_13_19_1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/cyto.b.22043","article-title":"Correlation Between a 10\u2010Color Flow Cytometric Measurable Residual Disease (MRD) Analysis and Molecular MRD in Adult B\u2010Acute Lymphoblastic Leukemia","volume":"102","author":"Singh J.","year":"2022","journal-title":"Cytometry. Part B, Clinical Cytometry"},{"issue":"11","key":"e_1_2_13_20_1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.clml.2018.06.030","article-title":"Comparison of Real\u2010Time Quantitative Polymerase Chain Reaction and Eight\u2010Color Flow Cytometry in Assessment of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia","volume":"18","author":"Hrabovsky S.","year":"2018","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"18","key":"e_1_2_13_21_1","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved Risk Classification for Risk\u2010Specific Therapy Based on the Molecular Study of Minimal Residual Disease (MRD) in Adult Acute Lymphoblastic Leukemia (ALL)","volume":"113","author":"Bassan R.","year":"2009","journal-title":"Blood"},{"issue":"3","key":"e_1_2_13_22_1","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical Significance of Minimal Residual Disease Quantification in Adult Patients With Standard\u2010Risk Acute Lymphoblastic Leukemia","volume":"107","author":"Br\u00fcggemann M.","year":"2006","journal-title":"Blood"},{"issue":"15","key":"e_1_2_13_23_1","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1002\/cncr.33529","article-title":"Prognostic Factors for Progression in Patients With Philadelphia Chromosome\u2010Positive Acute Lymphoblastic Leukemia in Complete Molecular Response Within 3 Months of Therapy With Tyrosine Kinase Inhibitors","volume":"127","author":"Sasaki K.","year":"2021","journal-title":"Cancer"},{"issue":"4","key":"e_1_2_13_24_1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","article-title":"Impact of Complete Molecular Response on Survival in Patients With Philadelphia Chromosome\u2010Positive Acute Lymphoblastic Leukemia","volume":"128","author":"Short N. J.","year":"2016","journal-title":"Blood"},{"issue":"5","key":"e_1_2_13_25_1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.23149","article-title":"Adolescents and Young Adults With Acute Lymphoblastic Leukemia Have a Better Outcome When Treated With Pediatric\u2010Inspired Regimens: Systematic Review and Meta\u2010Analysis","volume":"87","author":"Ram R.","year":"2012","journal-title":"American Journal of Hematology"},{"key":"e_1_2_13_26_1","doi-asserted-by":"crossref","first-page":"106235","DOI":"10.1016\/j.leukres.2019.106235","article-title":"Better Survivals in Adolescent and Young Adults, Compared to Adults With Acute Lymphoblastic Leukemia \u2010 A Multicenter Prospective Registry in Thai Population","volume":"87","author":"Limvorapitak W.","year":"2019","journal-title":"Leukemia Research"},{"issue":"8","key":"e_1_2_13_27_1","doi-asserted-by":"crossref","first-page":"e0256801","DOI":"10.1371\/journal.pone.0256801","article-title":"Association of Minimal Residual Disease With Clinical Outcomes in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era: A Systemic Literature Review and Meta\u2010Analysis","volume":"16","author":"Zhang W.","year":"2021","journal-title":"PLoS One"},{"issue":"15","key":"e_1_2_13_28_1","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","article-title":"Treatment of High\u2010Risk Philadelphia Chromosome\u2010Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL\u2010AR\u201003 Trial","volume":"32","author":"Ribera J. M.","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"e_1_2_13_29_1","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41375-019-0413-0","article-title":"Standardisation and Consensus Guidelines for Minimal Residual Disease Assessment in Philadelphia\u2010Positive Acute Lymphoblastic Leukemia (Ph\u2009+\u2009ALL) by Real\u2010Time Quantitative Reverse Transcriptase PCR of e1a2 BCR\u2010ABL1","volume":"33","author":"Pfeifer H.","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"e_1_2_13_30_1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2017.176917","article-title":"Predictive Value of Minimal Residual Disease in Philadelphia\u2010Chromosome\u2010Positive Acute Lymphoblastic Leukemia Treated With Imatinib in the European Intergroup Study of Post\u2010Induction Treatment of Philadelphia\u2010Chromosome\u2010Positive Acute Lymphoblastic Leukemia, Based on Immunoglobulin\/T\u2010Cell Receptor and BCR\/ABL1 Methodologies","volume":"103","author":"Cazzaniga G.","year":"2018","journal-title":"Haematologica"},{"issue":"7","key":"e_1_2_13_31_1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.clml.2024.02.009","article-title":"SOHO State of the Art Updates and Next Questions, Measurable Residual Disease in Philadelphia Chromosome\u2010Positive Acute Lymphoblastic Leukemia","volume":"24","author":"Short N. J.","year":"2024","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"9","key":"e_1_2_13_32_1","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.bbmt.2018.03.015","article-title":"Comparative Analysis of Flow Cytometry and RQ\u2010PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome\u2010Positive Acute Lymphoblastic Leukemia After Hematopoietic Stem Cell Transplantation","volume":"24","author":"Zhao X.","year":"2018","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"26","key":"e_1_2_13_33_1","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.24.00108","article-title":"Significance of Measurable Residual Disease in Adult Philadelphia Chromosome\u2010Positive ALL: A GRAAPH\u20102014 Study","volume":"42","author":"Kim R.","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"e_1_2_13_34_1","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/s41467-023-43171-9","article-title":"Minimal Residual Disease Detection by Next\u2010Generation Sequencing of Different Immunoglobulin Gene Rearrangements in Pediatric B\u2010ALL","volume":"14","author":"Chen H.","year":"2023","journal-title":"Nature Communications"}],"container-title":["International Journal of Laboratory Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijlh.70216","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijlh.70216","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijlh.70216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:29:05Z","timestamp":1786325345000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijlh.70216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,9]]},"references-count":33,"alternative-id":["10.1111\/ijlh.70216"],"URL":"https:\/\/doi.org\/10.1111\/ijlh.70216","archive":["Portico"],"relation":{},"ISSN":["1751-5521","1751-553X"],"issn-type":[{"value":"1751-5521","type":"print"},{"value":"1751-553X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,9]]},"assertion":[{"value":"2026-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ijlh.70216"}}